Circio Holding ASA operates in the healthcare sector, specializing in the research and development of advanced genetic medicines and immunotherapies. The company's pipeline is anchored by its proprietary circVec technology, a modular genetic cassette platform that enables the biogenesis of multifunctional circular RNAs (circRNAs) for gene and cell therapy applications. In addition to its platform technology, Circio is advancing TG01, a cancer vaccine targeting KRAS driver mutations that is undergoing clinical trials for multiple myeloma, pancreatic cancer, and lung cancer. Headquartered in Oslo, Norway, the company collaborates with major pharmaceutical and research partners to evaluate its delivery systems, including in vivo CAR-Macrophage and CAR-T therapies. Circio aims to build value primarily through its technology platform, seeking strategic partnerships to fund the development, testing, and commercialization of its therapeutic tools.
